Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

NCT07252479 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors (Phase 1)
RAS Mutation

Interventions

DRUG: AN9025 oral capsule

Sponsor

Adlai Nortye Biopharma Co., Ltd.